KASTLE THERAPS LLC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for KASTLE THERAPS LLC, and what generic alternatives to KASTLE THERAPS LLC drugs are available?
KASTLE THERAPS LLC has one approved drug.
There is one US patent protecting KASTLE THERAPS LLC drugs.
There are thirty-seven patent family members on KASTLE THERAPS LLC drugs in eleven countries.
Summary for KASTLE THERAPS LLC
| International Patents: | 37 |
| US Patents: | 1 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for KASTLE THERAPS LLC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kastle Theraps Llc | KYNAMRO | mipomersen sodium | SOLUTION;SUBCUTANEOUS | 203568-001 | Jan 29, 2013 | DISCN | Yes | No | 7,511,131 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for KASTLE THERAPS LLC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Kastle Theraps Llc | KYNAMRO | mipomersen sodium | SOLUTION;SUBCUTANEOUS | 203568-001 | Jan 29, 2013 | 7,407,943 | ⤷ Subscribe |
| Kastle Theraps Llc | KYNAMRO | mipomersen sodium | SOLUTION;SUBCUTANEOUS | 203568-001 | Jan 29, 2013 | 5,914,396 | ⤷ Subscribe |
| Kastle Theraps Llc | KYNAMRO | mipomersen sodium | SOLUTION;SUBCUTANEOUS | 203568-001 | Jan 29, 2013 | 7,101,993 | ⤷ Subscribe |
| Kastle Theraps Llc | KYNAMRO | mipomersen sodium | SOLUTION;SUBCUTANEOUS | 203568-001 | Jan 29, 2013 | 7,015,315 | ⤷ Subscribe |
| Kastle Theraps Llc | KYNAMRO | mipomersen sodium | SOLUTION;SUBCUTANEOUS | 203568-001 | Jan 29, 2013 | 6,451,991 | ⤷ Subscribe |
| Kastle Theraps Llc | KYNAMRO | mipomersen sodium | SOLUTION;SUBCUTANEOUS | 203568-001 | Jan 29, 2013 | 6,166,197 | ⤷ Subscribe |
| Kastle Theraps Llc | KYNAMRO | mipomersen sodium | SOLUTION;SUBCUTANEOUS | 203568-001 | Jan 29, 2013 | 6,222,025 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for KASTLE THERAPS LLC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 1569695 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 03097662 | ⤷ Subscribe |
| European Patent Office | 2336319 | ⤷ Subscribe |
| Japan | 2015198669 | ⤷ Subscribe |
| Portugal | 2336318 | ⤷ Subscribe |
| European Patent Office | 1419168 | ⤷ Subscribe |
| Denmark | 2174945 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
